Stella Sarma focuses her practice on EU, UK and Greek competition law, advising clients on merger control and global cartel investigations. She has unparalleled experience steering worldwide merger control proceedings in complex cross-border transactions before the European Commission and UK CMA, particularly in the technology and healthcare industries. She regularly guides multijurisdictional antitrust investigations at the EC, UK and national levels, especially in the automotive and tech sectors.
Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its acquisition of Eppo, a feature flagging and experimentation platform that will tightly integrate with Datadog’s existing product analytics suite.
Cooley advised Feedzai, a global leader in fraud and financial crime prevention, on its acquisition of Demyst, including Demyst’s Zonic data workflow orchestration platform, intellectual property and sophisticated data-integration capabilities.
Cooley advised Logik.ai, an industry leader offering a modern, artificial intelligence (AI)-powered, composable configure, price and quote solution, on its acquisition by ServiceNow (NYSE: NOW), the AI platform for business transformation.
EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca
March 17, 2025
Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical
March 17, 2025
Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.